EYES2024 ESE Young Endocrinologists and Scientists (EYES) 2024 Diabetes, Obesity and Metabolism (13 abstracts)
Low mitochondrial DNA is associated with post-COVID-19 syndrome in patients with type 2 diabetes
Yeva Ilkiv 1 , Anton Matviichuk 1 , Viktoriia Yerokhovych 1 , Dmytro Krasnenkov 2 , Veronika Korcheva 2 , Tetyana Falalyeyeva 3,4 , Pavlina Botsun 4 , Oksana Sulaieva 1,4 , Iuliia Komisarenko 1 & Nazarii Kobyliak 1,4
1Bogomolets National Medical University, Kyiv, Ukraine; 2Institute of Gerontology Academy of Medical Sciences of Ukraine, Kyiv, Ukraine; 3Taras Shevchenko National University of Kyiv, Kyiv, Ukraine; 4Medical Laboratory CSD, Kyiv, Ukraine
Introduction: Post-COVID-19 syndrome (PCS; long COVID-19, post-acute COVID-19, long-term effects of COVID-19) is an emerging health problem in people recovering from COVID-19 infection within the past 3-6 months. The study of COVID-19 severity markers and the assessment of PCS prognosis have encouraged the discovery of the molecular mechanisms responsible for PCS and inevitable pathological conditions. Aim: to define the links between mitochondrial (mt)-DNA levels in blood leukocytes and post COVID-19 syndrome (PCS) development in type 2 diabetes patient (T2D) with regard to clinical phenotype, gender, and biological age.
Methods: in this case-control study, 65 T2D patients were selected. Patients were divided on 2 group depending on PCS presence: PCS group (n = 44) and patient who didn’t develop PCS (n = 21) for up to 6 months after COVID-19 infection. A standardized qPCR method was used to measure the mt-DNA content.
Results: We observed significantly lower mt-DNA content in T2D patients with PCS as compared to those without it (1.26±0.25 vs 1.44±0.24; P = 0.011). In gender-specific and age-related analysis mt-DNA amount didn’t differ significantly between subgroups. In a comparative assessment depends on PCS clinical phenotype also a significant difference between mtDNA content not found (P = 0.572). In the stepwise multivariate logistic regression analysis, low mtDNA content was independent of oxygen, glucocorticoid therapy and COVID-19 severity associated with the PCS development. The mtDNA with a cut-off value ≤1.62 can be considered as a biomarker of PCS development in T2D patients with sensitivity – 93.2% and specificity – 42.9%. The AUROC for the model was 0.687 (95% CI 0.541-0.832; P = 0.012).
Conclusions: The low mtDNA content in leukocytes was associated with PCS development in T2D patients, and its decrease could be used as a potential diagnostic biomarker.
Article tools
My recent searches
My recently viewed abstracts
Authors
Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2024 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more